Why GOSS Stock Faces Bankruptcy or a 1,400% Upside
GOSS stock analysis: 80% crash triggers binary $0.16 biotech play — buy or sell? 👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends In this deep dive, we break down Gossamer Bio Inc (GOSS) and the strategic path forward for its lead pulmonary candidate, seralutinib. With shares trading at a distressed $0.16 following a massive 80% trial collapse and highly dilutive debt restructuring, the key question for investors is whether seralutinib's strong…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.